Loading people...
Felix Breyer is an Associate at Arix Bioscience, a global venture capital firm focused on investing in and building innovative life science companies. He plays a key role in identifying and evaluating potential investment opportunities.
Felix Breyer, as part of the Arix Bioscience team, focuses on investments in groundbreaking life science and biotechnology companies. This includes areas such as novel therapeutics, gene and cell therapies, precision medicine, and other advanced healthcare technologies.
Felix Breyer works at Arix Bioscience, a leading global venture capital company that specializes in investing in and developing breakthrough biotech companies.
Felix Breyer is an Investment Principal at M Ventures, the corporate venture capital arm of Merck KGaA, based in London, United Kingdom. He transitioned into the life sciences investment sector following an extensive academic career in scientific research. Breyer earned a Doctor of Philosophy from University College London and a Bachelor's Degree from the University of Dundee before entering the venture capital industry. In his current capacity, he evaluates, funds, and supports early-stage biotechnology, therapeutics, and healthcare companies on behalf of the global corporate venture fund. He leverages his advanced academic training in deep tech to facilitate research commercialization and guide emerging portfolio companies through their complex clinical development phases. Breyer currently focuses on deploying significant capital into innovative biotech startups while bridging the critical gap between academic scientific discovery and practical commercial healthcare applications.
Felix Breyer is an integral Associate at Arix Bioscience, a prominent global venture capital company dedicated to investing in and building innovative life science businesses. In his capacity, Felix is deeply involved in the critical early stages of investment, from identifying promising scientific advancements to conducting thorough due diligence on potential portfolio companies. His work directly supports Arix Bioscience's strategy of backing pioneering technologies and entrepreneurial teams that have the potential to transform healthcare.
At Arix Bioscience, Felix Breyer's investment focus areas align with the firm's broader mandate to target disruptive innovations in biotechnology and healthcare. This typically includes novel therapeutics, such as gene and cell therapies, precision medicine, drug discovery platforms, and other cutting-edge medical technologies designed to address significant unmet medical needs. Felix contributes to the rigorous evaluation process, assessing scientific merit, market potential, intellectual property, and management teams to ensure alignment with Arix's high standards for investment.
While specific details of Felix Breyer's career background are not publicly detailed, professionals in his role at Arix Bioscience typically possess a strong foundation in both scientific disciplines and finance. This often includes advanced degrees in life sciences, biotechnology, or related fields, coupled with experience in venture capital, investment banking, or strategic consulting within the healthcare sector. Such a background equips individuals like Felix with the analytical rigor and industry insight necessary to navigate the complex landscape of biotech investing and identify truly transformative opportunities.
As an Associate, Felix plays a vital role in the deal flow process, from initial screening and market analysis to financial modeling and supporting negotiations. His contributions are essential to Arix Bioscience's ability to identify and nurture companies that are poised to make a significant impact on human health. While specific notable investments directly attributed to Felix Breyer are part of the collaborative efforts of the Arix Bioscience team, his work contributes to the firm's overall success in building a robust portfolio of high-growth life science companies. His dedication helps ensure that Arix Bioscience continues to be a leader in fostering innovation within the global biotech ecosystem.
